ANTI-PHOSPHO-ANDROGEN RECEPTOR (SER81) ANTIBODY

General description

The X-linked androgen receptor (Dihydrotestosterone receptor; Nuclear receptor subfamily 3 group C member 4) is a member of the family of NR3 ligand-dependent transcription factors characterized by a ligand binding domain at the C-terminus, a central DNA-binding domain, and N-terminal transcription- activation domains. Androgen receptors are activated by steroid hormones such as testosterone and dihydrotestosterone. Activated androgen receptors translocate from the cytoplasm to the nucleus where they form homodimers that bind DNA. The androgen receptor associates with a number of adaptor-like proteins and functions as a complex that may induce or repress transcription depending on whether its associated proteins are co-activators or co-repressors that affect transcription possibly by modifying chromatin; co-activators are involved in histone acetylation and transcriptional activation whereas co-repressors are involved in histone deactylation and transcriptional repression. The androgen receptor is important for determining sex and male characteristics. Defective androgen receptors may play a role in Reifenstein syndrome, Kennedy disease, as well as prostate cancer.

Specificity

Detects Androgen Receptor (AR) only when phosphorylated on Ser81

Immunogen

KLH-conjugated synthetic peptide corresponding to amino acids including and surrounding Ser81 of human Androgen Receptor.

Application

Anti-phospho-Androgen Receptor (Ser81) Antibody is an antibody against phospho-Androgen Receptor (Ser81) for use in WB.

Research Category
Signaling

Epigenetics & Nuclear Function

Research Sub Category
Transcription Factors

Quality

Routinely evaluated by western blot on R1881 (methyltrienolone) treated LNCap lysates

Target description

110 kDa

Physical form

Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Analysis Note

Control
R1881 (methyltrienolone) treated LNCap lysates

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.